Risk-Benefit Assessment of Newer Versus Older Monoamine Oxidase (MAO) Inhibitors
- 1 April 1994
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 10 (4) , 292-300
- https://doi.org/10.2165/00002018-199410040-00003
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disordersInternational Clinical Psychopharmacology, 1993
- The Present Status of Monoamine Oxidase InhibitorsThe British Journal of Psychiatry, 1985
- Concomitant isocarboxazid/mianserin treatment of major depressive disorderJournal of Affective Disorders, 1984
- Monoamine Oxidase Inhibitors in Bipolar Endogenous DepressivesJournal of Clinical Psychopharmacology, 1981
- Combined Tricyclic—MAOI Therapy for Refractory Depression: A Review, with Guidelines for Appropriate UsageThe Journal of Clinical Pharmacology, 1978
- A Double-Blind Trial of Phenelzine and Amitriptyline in Depressed Out-Patients. a Possible Differential Effect of the Drugs on SymptomsThe British Journal of Psychiatry, 1973
- TREATMENT OF DEPRESSIVE ILLNESSES WITH COMBINED ANTIDEPRESSANTSThe Lancet, 1965
- Clinical Trial of the Treatment of Depressive IllnessBMJ, 1965
- A Controlled Trial of Iproniazid in the Treatment of Endogenous DepressionJournal of Mental Science, 1960
- Effects of Iproniazid in Depressive SyndromesBMJ, 1959